Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/9/15 → 04/27/17 |
Funding
- Boehringer Ingelheim Pharmaceutical: $11,220.00
A Prospective Randomised, Open Label, Blinded Endpoint(PROBE) Study to Evaluate Dual Antithrombotic Therapy with Dabigatran Etexilate(110mg and 150mg b.i.d)plus Clopidogrel or Ticagrelor vs.Triple Therapy Strategy with Warfarin(INR2.0-3.0)
- Lawson, William (CoPI)
- Gruberg, Luis (PI)
- Jeremias, Allen (CoPI)
Project: Research